Immuneering (IMRX) EBIAT (2020 - 2023)
Historic EBIAT for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.1 million.
- Immuneering's EBIAT fell 1387.58% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.5 million, marking a year-over-year decrease of 585.6%. This contributed to the annual value of -$53.5 million for FY2023, which is 585.6% down from last year.
- According to the latest figures from Q4 2023, Immuneering's EBIAT is -$15.1 million, which was down 1387.58% from -$12.6 million recorded in Q3 2023.
- Over the past 5 years, Immuneering's EBIAT peaked at -$3.6 million during Q2 2020, and registered a low of -$15.1 million during Q4 2023.
- In the last 4 years, Immuneering's EBIAT had a median value of -$11.5 million in 2022 and averaged -$10.1 million.
- Per our database at Business Quant, Immuneering's EBIAT plummeted by 12162.34% in 2021 and then soared by 193.95% in 2023.
- Over the past 4 years, Immuneering's EBIAT (Quarter) stood at -$5.8 million in 2020, then tumbled by 84.79% to -$10.8 million in 2021, then dropped by 22.82% to -$13.2 million in 2022, then decreased by 13.88% to -$15.1 million in 2023.
- Its EBIAT stands at -$15.1 million for Q4 2023, versus -$12.6 million for Q3 2023 and -$12.2 million for Q2 2023.